Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct 9;38(6):175.
doi: 10.1007/s13577-025-01308-6.

Establishment of human histiocytic sarcoma organoids dependent on the SHH/YAP pathway

Affiliations

Establishment of human histiocytic sarcoma organoids dependent on the SHH/YAP pathway

Yusuke Yoshimura et al. Hum Cell. .

Abstract

Histiocytic sarcoma is an extremely rare and aggressive malignant neoplasm characterized by immunophenotypic features of mature histiocytes. The mechanisms underlying its malignant transformation remain poorly understood; consequently, the development of effective therapies remains limited. Resected histiocytic sarcoma specimens were cultured using a modified air-liquid interface organoid method, serially passaged, and xenografted into NOD-scid IL2Rgnull mice. Tumors formed by xenografted organoids retained histological and genetic similarities with the original tumor. Genomic analysis revealed the activation of the Sonic Hedgehog signaling pathway and amplification of Yes-associated protein 1, a key effector of the Hippo pathway. Accordingly, we evaluated the sensitivity of the organoids to the Sonic Hedgehog inhibitor vismodegib and Yes-associated protein 1 inhibitor verteporfin, both of which demonstrated potent in vitro antitumor activity in organoid cultures. This model offers a valuable preclinical platform for investigating the molecular pathology of this rare malignancy and accelerating the development of targeted therapies.

Keywords: Histiocytic sarcoma; Organoid; Sonic Hedgehog; YAP1.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The authors declare that this study was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest. Ethical approval and informed consent to participate: The use of clinical materials for this study was approved by the Ethics Committee of Osaka International Cancer Institute (approval number: 1710059174-12), and all procedures were conducted in accordance with institutional and national ethical guidelines. Written informed consent was obtained from the patient.

References

    1. Facchetti F, Pileri SA, Lorenzi L, Tabanelli V, Rimsza L, Pittaluga S, et al. Histiocytic and dendritic cell neoplasms: what have we learnt by studying 67 cases. Virchows Archiv. 2017;471:467–89. - PubMed - DOI
    1. Dalia S, Shao H, Sagatys E, Cualing H, Sokol L. Dendritic cell and histiocytic neoplasms: biology, diagnosis, and treatment. Cancer Control. 2014;21(4):290–300. - PubMed - DOI
    1. Dalia S, Jaglal M, Chervenick P, Cualing H, Sokol L. Clinicopathologic characteristics and outcomes of histiocytic and dendritic cell neoplasms: the moffitt cancer center experience over the last twenty five years. Cancers. 2014;6(4):2275–95. - PubMed - PMC - DOI
    1. Pan Z, Xu ML. Histiocytic and dendritic cell neoplasms. Surg Pathol Clin. 2019;12(3):805–29. - PubMed - DOI
    1. Hung YP, Qian X. Histiocytic sarcoma. Arch Pathol Lab Med. 2020;144(5):650–4. - PubMed - DOI

MeSH terms

LinkOut - more resources